Ctd Holdings Inc (CTDH) 0.4500 $CTDH CTD Holdings Meets

New Post Public Reply Private Reply Replies (0) Message Board

Aug 30, 2016 at 1:06 PM

Ctd Holdings Inc (CTDH) 0.4500 $CTDH

CTD Holdings Meets With Parent Advocate Groups and Physicians
Marketwired - Tue Aug 16, 10:15AM CDT
Describes Proposed Clinical Trials for Intravenous Administration of Trappsol(R) Cyclo(TM) for the Treatment of Niemann-Pick Type C Disease

CTD Holdings Files Investigational New Drug Application With US FDA to Further Advance Its Drug Development Program
Marketwire Canada - Mon Aug 08, 6:00AM CDT
IND Describes Clinical Plans and Protocol to Fight the Rare and Fatal NPC Disease

CTD Holdings Files Clinical Trial Application With U.K. Regulatory Agency to Advance Its Drug Development Program
Marketwired - Mon Aug 01, 7:32AM CDT
Application Describes Clinical Plans and Protocol to Fight the Rare and Fatal Disease NPC

CTD Holdings Closes on $2 Million Private Placement
Marketwired - Tue Jun 07, 6:00AM CDT
William S. Shanahan, Former President of Colgate-Palmolive, Joins the Company's Board of Directors

CTD Holdings to Present "Management of Niemann-Pick Type C With Intravenous Hydroxypropyl- b -Cyclodextrin" at Ara Parseghian Medical Research Foundation Annual Conference
Marketwired - Tue May 03, 9:48AM CDT
CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present its findings on the intravenous treatment of Niemann-Pick Type C (NPC) patients at the annual conference of the Ara Parseghian Medical Research Foundation in Tucson, Arizona, June 4-7, 2016.

Global Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Pipeline Review 2015
M2 - Fri Jan 22, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8n22q/acid) has announced the addition of the "Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Overview - Therapeutics Development - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview - Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Comparative Analysis - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Development by Companies - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Products under Investigation by Universities/Institutes - Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development - CTD Holdings, Inc. - La Jolla Pharmaceutical Company - Merck & Co., Inc. - Okklo Life Sciences BV - Orphazyme ApS For more information visit http://www.researchandmarkets.com/research/h8n22q/acid
MRK: 62.73 (-0.28)

CTD Holdings plans divestiture of fine chemical unit to focus on biopharmaceutical business
M2 - Thu Jan 14, 5:57AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Wednesday that it proposes to divest its specialty fine chemical business to focus exclusively on drug development.

CTD Holdings Enters Into Letter of Intent to Sell Fine Chemical Unit
Marketwire Canada - Wed Jan 13, 6:24AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based biopharmaceuticals for the treatment of disease, today announced that it plans to sell its specialty fine chemical business in order to focus exclusively on drug development.

CTD Holdings' Clinical Trial Design Receives Positive Responses From U.K.'s Medicines and Healthcare Products Regulatory Agency
Marketwired - Mon Dec 14, 6:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, has received positive responses from a major U.K. healthcare regulator to the clinical trial design for its TrappsolÂ® Cyclo(TM) drug, which is used to treat Niemann-Pick Type C (NPC). NPC is a rare and fatal cholesterol metabolism disease found primarily in children and young adults.

CTD Holdings names Judge Joseph J. Farnan to board
M2 - Thu Nov 05, 4:28AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) revealed on Wednesday that it has appointed Judge Joseph J. Farnan to its board of directors.

Joseph J. Farnan, Jr. Joins CTD Holdings Board of Directors
Marketwired - Wed Nov 04, 11:31AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that Judge Joseph J. Farnan of the Wilmington, Delaware law firm, Farnan LLP, has joined its Board of Directors.

CTD Holdings appoints two new co-chairs to SAB
M2 - Tue Oct 27, 5:08AM CDT
Biotechnology company CTD Holdings (Other OTC:CTDH) disclosed on Monday that it has appointed Dr Rita Colwell and Dr Sharon Hrynkow as co chairs of its Scientific Advisory Board (SAB).

CTD Holdings Names Dr. Rita Colwell and Dr. Sharon Hrynkow Co-Chairs of Scientific Advisory Board
Marketwired - Mon Oct 26, 11:40AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) today announced Dr. Rita Colwell, Distinguished University Professor, University of Maryland at College Park and Johns Hopkins University Bloomberg School of Public Health, has joined their Scientific Advisory Board (SAB) and will co-chair the SAB with Dr. Sharon Hrynkow, Senior Vice President for Medical Affairs, CTD.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...